Lyell Immunopharma
CAR-T cell therapeutics for cancer
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Founded
- 2018
- Latest Form D
- $493M, Mar 2020
- Total capital
- $493M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $493M
- 1 Form D · last Mar 2020
- 79 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 34 pending · first 2024
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$493M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Catherine FriedmanDirectorNamed in SEC Form D filings
- Elizabeth HomansExecutive OfficerNamed in SEC Form D filings
- Hans BishopDirectorNamed in SEC Form D filings
- Heather TurnerExecutive OfficerNamed in SEC Form D filings
- Margo RobertsExecutive OfficerNamed in SEC Form D filings
- Nicholas RestifoExecutive OfficerNamed in SEC Form D filings
Show all 11 people
- Richard GooldExecutive OfficerNamed in SEC Form D filings
- Richard KlausnerExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Robert NelsonDirectorNamed in SEC Form D filings
- Stan RiddellExecutive OfficerNamed in SEC Form D filings
- Stephen HillExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- GrantedNR4A-DEFICIENT Cells Expressing C-jun And Uses ThereofUSPTOUS 12,679,879
- PendingBispecific Cars For The Treatment Of Lupus And Autoimmune DiseasesUSPTOApplication 18707423
- PendingChimeric Antigen Receptor SpacersUSPTOApplication 19322325
Show all 40 patent records
- NR4A-DEFICIENT Cells Expressing C-jun And Uses ThereofJul 14, 2026 · US 12,679,879Granted
- Bispecific Cars For The Treatment Of Lupus And Autoimmune DiseasesJun 4, 2026 · Application 18707423Pending
- Chimeric Antigen Receptor SpacersApr 9, 2026 · Application 19322325Pending
- Polynucleotides Targeting NR4A3 And Uses ThereofMar 26, 2026 · Application 18867057Pending
- Methods For Culturing CellsJan 8, 2026 · Application 19235216Pending
- Codon-optimized Nucleotide Sequences Encoding An AP-1 Transcription FactorSep 25, 2025 · Application 19071604Pending
- Methods For Culturing CellsJul 22, 2025 · US 12,365,871Granted
- Enhanced Immune Cell TherapyJul 17, 2025 · Application 18703185Pending
- Methods for Making, Compositions Comprising, and Methods of Using Rejuvenated T CellsMay 15, 2025 · Application 18807470Pending
- Codon-optimized Nucleotide Sequences Encoding An AP-1 Transcription FactorApr 8, 2025 · US 12,270,032Granted
- Novel Recombinant Cell Surface MarkersDec 12, 2024 · Application 18750174Pending
- ROR1 Targeting Chimeric Antigen ReceptorNov 19, 2024 · US 12,144,827Granted
- NR4A3-DEFICIENT Immune Cells And Uses ThereofNov 14, 2024 · Application 18564163Pending
- Methods For Making, Compositions Comprising, And Methods Of Using Rejuvenated T CellsSep 17, 2024 · US 12,091,682Granted
- Novel Recombinant Cell Surface MarkersAug 6, 2024 · US 12,054,531Granted
- Methods For Culturing CellsApr 25, 2024 · Application 18548006Pending
- Chimeric Activation ReceptorsDec 14, 2023 · Application 18250156Pending
- Methods For Culturing Cells Expressing C-junOct 5, 2023 · Application 18050414Pending
- Methods For Culturing Cells Expressing ROR1-BINDING ProteinOct 5, 2023 · Application 18050411Pending
- Methods Of Generating CellsJun 15, 2023 · Application 18050417Pending
- Methods For Culturing Immune CellsJun 9, 2022 · Application 17456374Pending
- Chimeric Antigen Receptor SpacersDec 9, 2021 · Application 17318996Pending
- Feeder Cell ReplacementApplication 63709271Pending
- IL-12 Stability VariantsApplication 19497341Pending
- T Cells Comprising A Chimeric Antigen Receptor Targeting Transforming Growth Factor Beta And A T Cell Receptor Targeting A Tumor Antigen, And Use ThereofApplication PCTUS2024053379Pending
- Chimeric PolypeptidesApplication 62964643Pending
- Chimeric PolypeptidesApplication 62964637Pending
- Bispecific Cars For The Treatment Of Lupus And Autoimmune DiseasesApplication PCTUS2024019750Pending
- Methods Of Culturing Reprogrammed CellsApplication PCTUS2024017729Pending
- Methods For Culturing Immune CellsApplication 63551053Pending
- Methods For Culturing NR4A-DEFICIENT Cells With Improved Culture MediumApplication 63632266Pending
- Bispecific Cars Targeting CD20/19 And Methods Of Use Of The SameApplication 63719052Pending
- Methods Of Treating Cancer By Administering Bispecific CD19/CD20 Car T CellsApplication 63824813Pending
- Feeder Cell ReplacementApplication 63725159Pending
- Immune Cell TherapyApplication PCTUS2023070469Pending
- Feeder Cell ReplacementApplication 63664692Pending
- Feeder Cell ReplacementApplication PCTUS2025035496Pending
- Methods Of Manufacturing Chimeric Antigen Receptor T CellsApplication PCTUS2023071707Pending
- Methods For Culturing Immune CellsApplication PCTUS2024035918Pending
- Methods For Culturing NR4A-DEFICIENT CellsApplication PCTUS2023075026Pending
Related companies, and why
- Tavo BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
- TEAMEDON INTERNATIONAL, INC.Similar federal contract value in Biotech · null in contracts
- Recourse Biologics, Inc.Similar federal contract value in Biotech · null in contracts
- Reviva Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Turn Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Codebreaker Tx, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .